Show/Hide Menu

Investor information

Financial guidance 2017

MorphoSys expects Group revenues for the 2017 financial year in the range of EUR 63 to 66 million. R&D expenses for proprietary drug development are expected to rise to EUR 96 to 100 million. The Company expects earnings before interest and taxes (EBIT) in a range of between EUR -66 to -71 million. This guidance does not include any potential in-licensing or co-development of further development candidates.

 

in € million

Guidance 2017

(updated Nov. 30, 2017)

Guidance 2017

(issued March 9, 2017)

Results 2016

 

Group Revenues 63 to 66 46 to 51 49.7
R&D expenses Proprietary Development 96 to 100 85 to 95 78.5
Group EBIT -66 to -85 -75 to -85 -59.9

Fundamentals of
MorphoSys Group

Business Segments

MorphoSys is one of the world’s leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing the next generation of therapeutic antibodies. MorphoSys is committed to create significant value for its employees, shareholders, customers and partners through a sustainable business strategy balancing short-term and long-term growth potentials. 

PARTNERED DISCOVERY

MorphoSys's Partnered Discovery segment business applies the Company's proprietary technologies to the research, development and optimization of therapeutic antibody drug candidates in partnerschips with pharmaceutical and biotechnology companies. While the development costs are borne by the respective partner, MorphoSys profits further from successful programs via milestone payments and potential royalties on product sales.

Please learn more about MorphoSys's partnered programs here.

PROPRIETARY DEVELOPMENT

In the second segment, Proprietary Development, MorphoSys develops innovative proprietary antibody products to generate added value for the Company. MorphoSys's scientists concentrate on indications such as inflammatory and autoimmune diseases, as well as cancer and infectious diseases. In this segment, the compounds are developed independently (or in a co-development setting) to proof clinical efficacy before being out-licensed to pharmaceutical or biotechnology companies for late-stage development and marketing.

More information about our proprietary product portfolio can be found here.

Related Links

Financial Reports

 
PDF-Download
Online Version
Order Printed Version

2017

  1. 3rd Quarter Interim Statement 2017

    Download
    Online
    Order
     
  2. Half-Year Report 2017

    Download
    Online
    Order
     
  3. 1st Quarter Interim Statement 2017

    Download
    Online
    Order
     

2016

  1. Annual Report 2016

    Download
    Online
    Order
  2. Financial Statements 2016 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. 3rd Quarter Interim Statement 2016

    Download
    Online
    Order
     
  4. Half-Year Report 2016

    Download
    Online
    Order
     
  1. 1st Quarter Interim Statement 2016

    Download
    Online
    Order
     

2015

  1. Financial Statements 2015 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  2. Consolidated Financial Statements (IFRS) 2015

    Download
    Online
    Order
     
  3. Nine Months' Report 2015

    Download
    Online
    Order
     
  4. Six Months' Report 2015

    Download
    Online
    Order
     
  5. Three Months’ Report 2015

    Download
    Online
    Order
     

2014

  1. Financial Statements 2014 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  2. Consolidated Financial Statements (IFRS) 2014

    Download
    Online
    Order
     
  3. Nine Months' Report 2014

    Download
    Online
    Order
     
  4. Six Months' Report 2014

    Download
    Online
    Order
     
  5. Three Months' Report 2014

    Download
    Online
    Order
     

2013

  1. Financial Statements 2013 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  2. Consolidated Financial Statements (IFRS) 2013

    Download
    Online
    Order
     
  3. Nine Months' Report 2013

    Download
    Online
    Order
     
  4. Six Months' Report 2013

    Download
    Online
    Order
     
  5. Three Months' Report 2013

    Download
    Online
    Order
     

2012

  1. Consolidated Financial Statements (IFRS) 2012

    Download
    Online
    Order
     
  2. Financial Statements 2012 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. Nine Months' Report 2012

    Download
    Online
    Order
     
  4. Six Months' Report 2012

    Download
    Online
    Order
     
  5. Three Months' Report 2012

    Download
    Online
    Order
     

2011

  1. Consolidated Financial Statements (IFRS) 2011

    Download
    Online
    Order
     
  2. Financial Statements 2011 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. Nine Months' Report 2011

    Download
    Online
    Order
     
  4. Six Months' Report 2011

    Download
    Online
    Order
     
  5. Three Months' Report 2011

    Download
    Online
    Order
     

2010

  1. Consolidated Financial Statements (IFRS) 2010

    Download
    Online
    Order
     
  2. Financial Statements 2010 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. Nine Months' Report 2010

    Download
    Online
    Order
     
  4. Six Months' Report 2010

    Download
    Online
    Order
     
  5. Three Months’ Report 2010

    Download
    Online
    Order
     

Investor Relations
Presentations

Date
Venue
Download

2018

  1. 02/15/2018
    LEERINK Partners 7th Annual Global Healthcare Conference
  2. 01/15/2018
    Kepler Cheuvreux German Corporate Conference
  3. 01/10/2018
    36th Annual J.P. Morgan Healthcare Conference

2017

  1. 12/12/2017
    Investor & Analyst Presentation after the 2017 ASH Annual Meeting
  2. 12/06/2017
    Berenberg European Conference 2017
  3. 11/27/2017
    Deutsches Eigenkapitalforum 2017
  4. 11/16/2017
    Bryan Garnier Healthcare Conference
  5. 11/07/2017
    Q3 2017 Financial Results
  6. 09/20/2017
    Baader Investment Conference
  7. 09/18/2017
    Berenberg and Goldman Sachs Sixth German Corporate Conference
  8. 09/05/2017
    Capital Markets Day Company Update
  9. 08/29/2017
    Commerzbank Sector Conference
  10. 08/03/2017
    Q2 2017 Financial Results
  11. 06/22/2017
    dbAccess Berlin Conference
  12. 06/05/2017
    Investor Event ASCO 2017
  13. 05/22/2017
    UBS Global Healthcare Conference
  14. 05/04/2017
    Q1 2017 Financial Results
  15. 04/19/2017
    10th Kempen Life Sciences Conference
  16. 04/05/2017
    Roadshow Boston & New York
  17. 03/09/2017
    Year End 2016